Thoracic radiotherapy of limited-stage small cell lung cancer : current situation of dose fractionation
10.3760/cma.j.cn113030-20210518-00191
- VernacularTitle:局限期小细胞肺癌胸部放疗剂量分割现状
- Author:
Tianyou ZHAN
1
;
Zongmei ZHOU
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Neoplasm, small cell lung/radiotherapy;
Dose fractionation;
Current situation
- From:
Chinese Journal of Radiation Oncology
2022;31(3):284-287
- CountryChina
- Language:Chinese
-
Abstract:
Thoracic radiotherapy is a major treatment and dose fractionation remains controversial in limited-stage small cell lung cancer. Twice-daily (BID) radiotherapy, as a standard protocol established in prospective studies, is often replaced by other treatment strategies in clinical practice due to the occurrence of side effects and inconvenience. In addition, in inoperable stage Ⅰ small cell lung cancer with negative lymph nodes, stereotactic ablative radiotherapy (SABR) provides a new option for some elderly patients who are expected to be unable to tolerate long-term radiotherapy. The appropriate dose fractionation scheme can both ensure the therapeutic effects and reduce toxic effects. This article reviews the research of limited-stage small cell lung cancer about dose fractionation.
